PRESS RELEASE: US FDA Expanded Access for DeltaRex-G

United States FDA Grants Expanded Access for DeltaRex-G, a Precision Tumor Targeted Genetic Medicine for Metastatic Cancer(s)

PRESS RELEASE: DeltaRex-G - A cure for pancreas cancer in 2019?

DeltaRex-G induces 10-year Remission in a Stage IV Pancreatic Cancer Patient

PRESS RELEASE: Exploiting the oncogenic drivers of the CCNG1 pathway

DeltaRex-G generates significant interest in a Commentary published in Molecular Therapy Family of Journals, the Official Organ of the American Society of Gene and Cell Therapy (ASGCT).